Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota’s Medical Cannabis Program

/by

Authors: Susan P Anderson, Dylan M Zylla, Deepa M McGriff, Tom J Arneson Published in Journal of Oncology Practice April 2019 Abstract Purpose: Minnesota’s medical cannabis program is unique, in that it routinely collects patient-reported scores on symptoms. This article focuses on changes in symptom severity reported by patients with cancer during their first 4 months…

Read more

Oncology Clinicians and the Minnesota Medical Cannabis Program: A Survey on Medical Cannabis Practice Patterns, Barriers to Enrollment, and Educational Needs

/by

Authors: Dylan Zylla, Grant Steele , Justin Eklund, Jeanne Mettner, Tom Arneson Published in Cannabis and cannabinoid research October 2018 Abstract Background:Medical cannabis has been available in the State of Minnesota since July 2015 through the Minnesota Medical Cannabis Program (MMCP). Objectives: Our study aimed to delineate oncology providers’ views on medical cannabis, identify barriers…

Read more

Cannabis and Cancer Survey

/by

Investigators from the Cancer Research Center would like to better understand the opinions of patients and/or their loved ones about the use of medical cannabis.

Read more

Cannabinoids in Urology. Which Benign Conditions Might They Be Appropriate to Treat: A Systematic Review

/by

Authors: Brian Robert Peter Birch, Charlie Taylor Published in Urology November 2020 Abstract There is growing evidence suggesting cannabinoids may provide suitable alternatives to conventional treatments in an increasing number of clinical settings. This review evaluates how cannabinoids are used to treat certain benign urologicalpathologies and to clarify the clinical value of this data. This…

Read more

FURTHER EVIDENCE OF ANXIETY- AND DEPRESSION-LIKE BEHAVIOR FOR TOTAL GENETIC ABLATION OF CANNABINOID RECEPTOR TYPE 1

/by

Authors: Delia Soriano, Alicia Brusco, Laura Caltana Published in Behavioural Brain Research November 2020 Abstract Cannabinoid receptor type 1 (CB1R) is the most abundant cannabinoid receptor in central nervous system. Clinical studies and animal models have shown that the attenuation of endocannabinoid system signaling correlates with the development of psychiatric disorders such as anxiety, depression…

Read more

Cannabis Medicines & the World Health Organization

/by

A video update from Kenzi Riboulet-Zemouli and Michael Krawitz on the World Health Organization’s recommendations on cannabis scheduling and international cannabis law.

Read more

Cannabis Use May Reduce Healthcare Utilization and Improve Hospital Outcomes in Patients with Cirrhosis

/by

Authors: Lindsay A. Sobotka, Khalid Mumtaz, Alice Hinton, Sean G. Kelly, Lanla F. Conteh, Anthony J. Michaels, A. James Hanje, Michael R. Wellnera Published in Annals of Hepatology November 2020 Abstract Introduction and Objectives:  Previous studies reveal conflicting data on the effect of cannabis use in patients with cirrhosis. This research evaluates the impact of…

Read more

Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression

/by

Authors: Jianfeng Wang, Yunze Xu, Yun Zou, Liangsong Zhu, Baijun Dong, Jiwei Huang, Yonghui Chen, Wei Xue, Yiran Huang, Wen Kong & Jin Zhang Published in Tumor Biology October 2016 Abstract Renal cell carcinoma (RCC) is a common urologic tumor with a poor prognosis. Cannabinoid receptor 1 (CB1), which is a G protein-coupled receptor, has recently…

Read more

Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD

/by

Authors: Joshua L. Rein, Christina M. Wyatt Published in American Journal of Kidney Diseases August 2017 Abstract Marijuana is the most commonly used recreational drug in the United States, and legal recreational and medicinal use has gained public acceptance during the last decade. Twenty-nine US states have established medical marijuana programs, 8 of which have also…

Read more

Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy

/by

Authors: Partha Mukhopadhyaya, Mohanraj Rajesha, Hao Pan, Vivek Patel, Bani Mukhopadhyaya, Sándor Bátkai, Bin Gao, György Haskóc, Pál Pachera Published in Journal of Pain and Symptom Management February 2010 Abstract Cisplatin is an important chemotherapeutic agent; however, its nephrotoxicity limits its clinical use. Enhanced inflammatory response and oxidative/nitrosative stress seem to play a key role in…

Read more

Nephrologist Views Regarding Cannabinoid Use in Advanced Chronic Kidney Disease and Dialysis: A Survey

/by

Authors: David Collister, MD, PhD, Karthik Tennankore, MD, SM, Sara N. Davison, MD, MHSc, Ron Wald, MD, MPH, Christian Rabbat, MD, MSc, Michael Walsh, MD, PhD Published in Journal of Pain and Symptom Management August 2020 Abstract Context: The efficacy and safety of cannabinoids to treat symptoms in individuals with kidney disease is uncertain. Objectives: We sought to…

Read more

Cannabigerol (CBG) Survey Study

/by

A team of cannabis researchers is investigating the use of cannabis containing the cannabinoid cannabigerol (CBG) and people’s experiences with it.

Read more